keyword
MENU ▼
Read by QxMD icon Read
search

Enoxaparin

keyword
https://www.readbyqxmd.com/read/28221043/radiolabeled-111-in-fgf-2-is-suitable-for-in-vitro-ex-vivo-evaluations-and-in-vivo-imaging
#1
Alessandra Moscaroli, Gabriel Jones, Tessa Lühmann, Lorenz Meinel, Stephanie Wälti, Alain Blanc, Eliane Fischer, Manuel Hilbert, Roger Schibli, Martin Béhé
Fibroblast growth factor-2 (FGF-2) is a potent modulator of cell growth and regulation, with improper FGF-2 signaling being involved in impaired responses to injury or even cancer. Therefore, the exploitation of FGF-2 as a therapeutic drives the prerequisite for effective insight into drug disposition kinetics. In this article, we present an (111)In-radiolabeled FGF-2 derivative for noninvasive imaging in small animals deploying single photon emission tomography (SPECT). (111)In-FGF-2 is equally well suitable for in vitro and ex vivo investigations as (125)I-FGF-2...
February 21, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28220880/parenteral-administration-of-factor-xa-iia-inhibitors-limits-experimental-aortic-aneurysm-and-atherosclerosis
#2
Corey S Moran, Sai-Wang Seto, Smriti M Krishna, Surabhi Sharma, Roby J Jose, Erik Biros, Yutang Wang, Susan K Morton, Jonathan Golledge
Intraluminal thrombus is a consistent feature of human abdominal aortic aneurysm (AAA). Coagulation factor Xa (FXa) catalyses FII to thrombin (FIIa). We examined the effect of FXa/FIIa inhibition on experimental aortic aneurysm in apolipoprotein E-deficient (ApoE(-/-)) mice infused with angiotensin II (AngII). The concentration of FXa within the supra-renal aorta (SRA) correlated positively with SRA diameter. Parenteral administration of enoxaparin (FXa/IIa inhibitor) and fondaparinux (FXa inhibitor) over 14 days reduced to severity of aortic aneurysm and atherosclerosis in AngII-infused ApoE(-/-) mice...
February 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28205078/enoxaparin-dose-reduction-for-thrombocytopenia-in-patients-with-cancer-a-quality-assessment-study
#3
Simon Mantha, Yimei Miao, Jonathan Wills, Rekha Parameswaran, Gerald A Soff
The development of thrombocytopenia in the setting of therapeutic anticoagulation for venous thromboembolic disease (VTE) is common in cancer patients, but guidelines for management are based on limited past data and have not been validated. In 2011, Memorial Sloan Kettering Cancer Center (MSKCC) implemented the following guidelines in this setting: administer full dose enoxaparin for a platelet count > 50,000/mcL, half-dose enoxaparin for a platelet count of 25,000-50,000/mcL, and hold anticoagulation for a platelet count < 25,000/mcL...
February 16, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28197755/direct-oral-anticoagulants-for-extended-duration-thromboprophylaxis-in-hospitalized-medically-ill-patients-are-we-there-yet
#4
Majed S Al Yami, Osamah M Alfayez, Sawsan M Kurdi, Razan Alsheikh
Despite a recommended 7-10 days of thromboprophylaxis, medically ill patients remain at increased risk of developing venous thromboembolism (VTE) after hospital discharge. Here, we present a contemporary review on the efficacy and safety of extended-duration thromboprophylaxis with direct oral anticoagulants (DOACs) in hospitalized medically ill patients. A search of publication and trial databases of controlled trials conducted from 2010 to 2016 using the key terms apixaban, rivaroxaban, and betrixaban showed three phase III trials that met our search criteria...
February 14, 2017: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/28185392/thrombotic-valvular-dysfunction-with-transcatheter-mitral-interventions-for-postsurgical-failures
#5
Marvin H Eng, Adam Greenbaum, Dee Dee Wang, Janet Wyman, Dnp, Heider Arjomand, Pradeep Yadav, Hassan Nemeh, Gaetano Paone, Mayra Guerrero, William O'Neill
BACKGROUND: Degenerated surgical mitral valve repairs or surgical prostheses are currently being treated with transcatheter mitral valve replacement (TMVR). We report the procedural and mid-term assessment of thirteen cases. METHODS: From 12/2013 to 12/2015, 13 consecutive patients with degenerated mitral valve repair or valve replacement were treated. Patients were assessed for mitral valve academic valve consortium (MVARC) defined outcomes. RESULTS: Immediate procedural MVARC defined technical success was 92%...
February 10, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28185212/economic-evaluations-of-new-oral-anticoagulants-for-the-prevention-of-venous-thromboembolism-after-total-hip-or-knee-replacement-a-systematic-review
#6
REVIEW
James Brockbank, Sorrel Wolowacz
BACKGROUND: Total hip replacement (THR) and total knee replacement (TKR) surgeries are being performed with increasing regularity and are associated with a high risk of developing a venous thromboembolism (VTE). New oral anticoagulants (NOACs) may be more effective at preventing VTEs but are associated with more bleeding events versus traditional anticoagulants. OBJECTIVE: The objective of this systematic review was to identify published economic analyses of NOACs for primary VTE prophylaxis following THR and TKR surgeries, and to summarise the modelling techniques used and the cost-effectiveness results...
February 10, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28181177/outcomes-associated-with-generic-drugs-approved-using-product-specific-determinations-of-therapeutic-equivalence
#7
Joshua J Gagne, Jennifer M Polinski, Wenlei Jiang, Sarah K Dutcher, Jing Xie, Joyce Lii, Lisa A Fulchino, Aaron S Kesselheim
OBJECTIVE: We sought to examine rates of clinical outcomes among patients before and after market introduction of generic versions of five drugs approved using product-specific equivalence determinations. METHODS: We used data from a large national insurer to identify patients who initiated a study (acarbose tablets, salmon calcitonin nasal spray, enoxaparin injection, vancomycin capsules, venlafaxine extended-release tablets) or control drug (nateglinide, glimepiride, alendronate, fondaparinux, metronidazole, sertraline, paroxetine) in each calendar month between 2003 and 2012 and to determine rates of claims-based proxies for lack of effectiveness outcomes following initiation...
February 8, 2017: Drugs
https://www.readbyqxmd.com/read/28180233/abnormal-vaginal-bleeding-in-women-with-venous-thromboembolism-treated-with-apixaban-or-warfarin
#8
Marjolein P A Brekelmans, Luuk J J Scheres, Suzanne M Bleker, Barbara A Hutten, Anne Timmermans, Harry R Büller, Saskia Middeldorp
Abnormal vaginal bleeding can complicate direct oral anticoagulant (DOAC) treatment. We aimed to investigate the characteristics of abnormal vaginal bleeding in patients with venous thromboembolism (VTE) receiving apixaban or enoxaparin/warfarin. Data were derived from the AMPLIFY trial. We compared the incidence of abnormal vaginal bleeding between patients in both treatment arms and collected information on clinical presentation, diagnostic procedures, management and outcomes. In the AMPLIFY trial, 1122 women were treated with apixaban and 1106 received enoxaparin/warfarin...
February 9, 2017: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/28174415/comparison-of-enoxaparin-and-rivaroxaban-in-balance-of-anti-fibrinolysis-and-anticoagulation-following-primary-total-knee-replacement-a-pilot-study
#9
Jinwei Xie, Jun Ma, Qiang Huang, Chen Yue, Fuxing Pei
BACKGROUND This study aimed to assess whether the efficacy of tranexamic acid (TXA) would be altered when rivaroxaban or enoxaparin was used for thromboprophylaxis in primary total knee replacement (TKR). It was hypothesized that the hemostatic effect of TXA would be better with the use of enoxaparin. MATERIAL AND METHODS A randomized clinical trial was conducted on 194 patients undergoing primary TKR for osteoarthritis. An intravenous dose of 15 mg/kg (TXA) and 1 g topical TXA were used. Patients randomly received enoxaparin or rivaroxaban prophylaxis when the drainage was less than 30 ml/h 6-8 h postoperatively...
February 8, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28163175/thrombosis-of-the-inferior-vena-cava-after-endovascular-aortic-repair-in-a-patient-with-may-thurner-syndrome-case-report-and-literature-review
#10
Firouza Dahi, Asimakis Gkremoutis, Marc Harth, Thomas Schmitz-Rixen, Michael Keese
Inferior vena cava (IVC) thrombosis is a rare complication of abdominal aortic aneurysm (AAA). A 70-year-old male patient of Italian origin presented with a 9.3 x 8.4 cm infrarenal AAA, which was treated by endovascular aortic repair (EVAR). He reported a history of ulcerative colitis and was on prednisolone 80 mg daily. Seven weeks postoperatively the patient was readmitted with a deep vein thrombosis including both iliac veins and IVC, and bilateral pulmonary embolism. Venous thrombectomy and decompression of the IVC was performed by partial resection of the aneurysm sac...
February 2, 2017: Annals of Vascular Surgery
https://www.readbyqxmd.com/read/28161565/dual-antiplatelet-therapy-does-not-increase-the-risk-of-bleeding-after-carotid-endarterectomy-results-of-a-prospective-study
#11
Giulio Illuminati, Fabrice Schneider, Giulia Pizzardi, Federica Masci, Francesco G Calio, Jean-Baptiste Ricco
BACKGROUND: The purpose of this study was to evaluate the risk of bleeding and other postoperative complications of carotid endarterectomy (CEA) in patients receiving dual antiplatelet therapy (DAPT). METHODS: From January 2005 to December 2015, 188 consecutive patients undergoing CEA and receiving DAPT (aspirin 100 mg + clopidogrel 75 mg) were enrolled in a prospective study. All of them underwent coronary artery stenting with drug-eluting stents during the 6 months preceding CEA...
February 1, 2017: Annals of Vascular Surgery
https://www.readbyqxmd.com/read/28156170/passive-targeting-and-lung-tolerability-of-enoxaparin-microspheres-for-a-sustained-antithrombotic-activity-in-rats
#12
Shaimaa S Ibrahim, Rihab Osman, Nahed D Mortada, Ahmed-Shawky Geneidy, Gehanne A S Awad
Pulmonary bed can retain microparticles (MP) larger than their capillaries' diameter, hence we offer a promising way for lung passive targeting following intravenous (IV) administration. In this study, enoxaparin (Enox)-albumin microspheres (Enox-Alb MS) were, optimally, developed as lung targeted sustained release MP for IV use. Lung tolerability and targeting efficiency of Enox-Alb MS were tested, and the pharmacokinetic profile following IV administration to albino rats was constructed. In vivo studies confirmed high lung targeting efficiency of Enox-Alb MS with lack of potential tissue toxicity...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/28153659/enoxaparin-for-the-prevention-of-preeclampsia-and%C3%A2-intrauterine-growth-restriction-in-women-with%C3%A2-a%C3%A2-history-%C3%A2-a%C3%A2-randomized-trial
#13
Katie M Groom, Lesley M McCowan, Laura K Mackay, Arier C Lee, Joanne M Said, Stefan C Kane, Susan P Walker, Thijs E van Mens, Natalie J Hannan, Stephen Tong, Larry W Chamley, Peter R Stone, Claire McLintock
BACKGROUND: Preeclampsia and small-for-gestational-age pregnancy are major causes of maternal and perinatal morbidity and mortality. Women with a previous pregnancy affected by these conditions are at an increased risk of recurrence in a future pregnancy. Past trials evaluating the effect of low-molecular-weight heparin for the prevention of recurrence of preeclampsia and small-for-gestational-age pregnancy have shown conflicting results with high levels of heterogeneity displayed when trials were compared...
January 30, 2017: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28152898/safety-of-using-escalated-doses-of-enoxaparin-prophylaxis-in-adults-with-acute-lymphoblastic-leukemia-receiving-asparaginase-based-intensification-therapy
#14
Jack Toshimine Seki, Tian Wang, Lalit Saini, Andrew Stessman, Joseph Samuel, Naoko Sakurai, Andre C Schuh, Karen W L Yee, Mark D Minden, Aaron David Schimmer, Vikas Gupta, Mohamed Shanavas, Joseph M Brandwein
: 141 Background: Venous thromboembolism (VTE) is a known complication in adults receiving asparaginase (ASNase) for acute lymphoblastic leukemia (ALL). We previously reported a 27.3% VTE rate in patients (pts) receiving a modified Dana Farber Cancer Institute (DFCI).We report updated results using two different dosing of enoxaparin as primary VTE prophylaxis. METHODS: 62 pts ALL in complete remission, who were treated with a weekly ASNase-based DFCI intensification phase for at least 7 cycles (21 weeks) and received prophylaxis with enoxaparin targeted to 1 mg/kg subcutaneously (SC) daily (escalated dose group), were evaluated ...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152224/effect-of-plasmapheresis-on-the-antifactor-xa-activity-of-enoxaparin-in-an-obese-adolescent-patient
#15
K W Rahawi, K L Higgins, C Noda, J S Stultz
To our knowledge, the effect of plasmapheresis on the antifactor Xa activity of enoxaparin has never been reported. We describe a 13-year-old, obese (92-kg) adolescent female who was treated with enoxaparin for a pulmonary embolism while receiving plasmapheresis for suspected autoimmune encephalitis, and experienced clinically significant reductions in antifactor Xa activity following plasmapheresis. She received five courses of plasmapheresis, with the final two during treatment with enoxaparin. Her antifactor Xa concentrations were highly variable, and we hypothesized that plasmapheresis was affecting these levels...
February 2, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28132398/modulation-of-antiphospholipid-antibodies-induced-trophoblast-damage-by-different-drugs-used-to-prevent-pregnancy-morbidity-associated-with-antiphospholipid-syndrome
#16
Angela M Alvarez, Norman Balcázar, Sebastián San Martín, Udo R Markert, Angela P Cadavid
PROBLEM: Women with antiphospholipid antibodies (aPLs) present a risk of pregnancy morbidity (PM), vascular thrombosis (VT), or both (PM/VT). aPLs affect trophoblast function, and the aim of this study was to determine the modulation of this aPL-induced damage by different drugs. METHOD OF STUDY: IgG was obtained from women with PM and PM/VT positive to aPLs. Binding of IgG to trophoblastic cells, proliferation, mitochondrial membrane integrity, and trophoblast invasion were assessed...
January 29, 2017: American Journal of Reproductive Immunology: AJRI
https://www.readbyqxmd.com/read/28128085/antiphospholipid-syndrome-with-anti%C3%AE-2glicoprotein-1-antibodies-as-the-cause-of-recurrent-tibial-vein-thrombosis-in-sapho-syndrome
#17
Hanna Przepiera-Będzak, Marek Brzosko
The antiphospholipid antibody syndrome is defined by the presence of antiphospholipid antibodies in patients with recurrent venous or arterial thromboembolism (1). SAPHO syndrome is a rare disease, characterized by specific clinical manifestations of synovitis, acne pustulosis, hyperostosis, and osteitis. It is a disease that manifests with a combination of osseous and articular manifestations associated with skin lesions (2). Venous thrombosis complicating SAPHO syndrome seems to be uncommon with an unclear pathogenesis (3-9)...
December 2016: Acta Dermatovenerologica Croatica: ADC
https://www.readbyqxmd.com/read/28121820/enoxaparin-and-aspirin-compared-with-aspirin-alone-to-prevent-placenta-mediated-pregnancy-complications-a-randomized-controlled-trial
#18
Suzanne Demers, Emmanuel Bujold, Stéphanie Roberge
No abstract text is available yet for this article.
February 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28120516/once-versus-twice-daily-enoxaparin-for-the-initial-treatment-of-acute-venous-thromboembolism
#19
Javier Trujillo-Santos, Jean François Bergmann, Bortoluzzi Cristiano, Raquel López-Reyes, Matteo Giorgi-Pierfransceschi, Juan Bosco López-Sáez, Paola Ferrazzi, José Bascuñana, José María Suriñach, Manuel Monreal
BACKGROUND: In patients with acute venous thromboembolism (VTE), it is uncertain whether enoxaparin should be administered twice or once daily. METHODS: We used the RIETE Registry data to compare the 15- and 30-day rates of VTE recurrences, major bleeding and death between patients receiving enoxaparin twice vs. once daily. We used propensity score-matching to adjust for confounding variables. RESULTS: The study included 4,730 patients: 3,786 (80%) received enoxaparin twice daily and 944 once daily...
January 25, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28116117/predictive-factors-for-effectiveness-and-safety-of-enoxaparin-for-total-knee-arthroplasty-in-aged-japanese-patients-a-retrospective-review
#20
Akihiro Sonoda, Yuki Kondo, Yasuhiro Tsuneyoshi, Yoshitaka Iwashita, Shoji Nakao, Kazuhisa Ishida, Kentaro Oniki, Junji Saruwatari, Tetsumi Irie, Yoichi Ishitsuka
BACKGROUND: The aims of this study were to investigate predictive factors involved in effectiveness and safety of enoxaparin for prevention of postoperative venous thromboembolism in aged Japanese total knee arthroplasty (TKA) patients. METHODS: Japanese patients over 65 years old who were administered enoxaparin for TKA were enrolled in this study. Their medical records were retrospectively reviewed. Data were corrected at the Izumi Regional Medical Center, from September 2009 to March 2014...
2017: Journal of Pharmaceutical Health Care and Sciences
keyword
keyword
20493
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"